Maxwell Laurans

Maxwell Laurans

Auto-generated profile, based on publicly available information

Maxwell Laurans

Department of Neurosurgery, Yale School of Medicine, New Haven, CT, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in World Neurosurgery
Verified
Journal Article
Closed access
Aladine A. ElsamadicyAladine A. Elsamadicy
Aladine A. Elsamadicy
MSMani Ratnesh S. Sandhu
Mani Ratnesh S. Sandhu
IFIsaac G. Freedman
Isaac G. Freedman
BRBenjamin C. Reeves
Benjamin C. Reeves
AKAndrew B. Koo
Andrew B. Koo
MLMaxwell Laurans
Maxwell Laurans

11 January 2022 in Global Spine Journal
Verified
Journal Article
Open access
PDF file
Aladine A. ElsamadicyAladine A. Elsamadicy
Aladine A. Elsamadicy
AKAndrew B. Koo
Andrew B. Koo
BRBenjamin C. Reeves
Benjamin C. Reeves
Zach PenningtonZach Pennington
Zach Pennington
MSMargot Sarkozy
Margot Sarkozy
Daniel M. SciubbaDaniel M. Sciubba
Daniel M. Sciubba
The Hospital Frailty Risk Score (HFRS) is a metric that measures frailty among patients in large national datasets using ICD-10 codes. While other metrics have been utilized to demonstrate the association between frailty and poor outcomes in spine oncology, none have examined the HFRS. The aim of this study was to investigate the impact of frailty using the HFRS on complications, length of stay, cost of admission, and discharge disposition in patients undergoing surgery for primary tumors of the spinal cord and meninges. A retrospective cohort study was performed using the Nationwide Inpatient Sample database from 2016 to 2018. Adult patients undergoing surgery for primary tumors of the spinal cord and meninges were identified using ICD-10-CM codes. Patients were categorized into 2 cohorts based on HFRS score: Non-Frail (HFRS<5) and Frail (HFRS≥5). Patient characteristics, treatment, perioperative complications, LOS, discharge disposition, and cost of admission were assessed. Of the 5955 patients identified, 1260 (21.2%) were Frail. On average, the Frail cohort was nearly 8 years older (P < .001) and experienced more postoperative complications (P = .001). The Frail cohort experienced longer LOS (P < .001), a higher rate of non-routine discharge (P = .001), and a greater mean cost of admission (P < .001). Frailty was found to be an independent predictor of extended LOS (P < .001) and non-routine discharge (P < .001). Our study is the first to use the HFRS to assess the impact of frailty on patients with primary spinal tumors. We found that frailty was associated with prolonged LOS, non-routine discharge, and increased hospital costs.

1 August 2020 in The Annals of Thoracic Surgery
Verified
Journal Article
Open access
DBDaniel J. Boffa
Daniel J. Boffa
BJBenjamin L. Judson
Benjamin L. Judson
KBKevin G. Billingsley
Kevin G. Billingsley
DGDomenico Galetta
Domenico Galetta
PFPaul Fontanez
Paul Fontanez
NANita Ahuja
Nita Ahuja
The Covid-19 pandemic has created unprecedented disruption in health care delivery around the world. In an effort to prevent hospital-acquired Covid-19 infections, most hospitals have severely curtailed elective surgery, performing only surgeries if the patient's survival or permanent function would be compromised by a delay in surgery. As hospitals emerge from the pandemic, it will be necessary to progressively increase surgical activity at a time when hospitals continue to care for Covid-19 patients. In an attempt to mitigate the risk of nosocomial infection, we have created a patient care pathway designed to minimize risk of exposure of patients coming in to the hospital for scheduled procedures. The "Covid-minimal surgery pathway" is a predetermined patient flow, that dictates the locations, personnel and materials that come in contact with our cancer surgery population, designed to minimize risk for virus transmission. We outline the approach that allowed a large academic medical center to create a Covid-minimal cancer surgery pathway within 7 days of initiating discussions. Although the pathway represents a combination of recommended practices, there is not data to support its efficacy. We share the pathway concept and our experience so that others wishing to similarly align staff and resources towards the protection of patients, may have an easier time navigating the process.

1 July 2021 in World Neurosurgery
Verified
Journal Article
Closed access
Aladine A. ElsamadicyAladine A. Elsamadicy
Aladine A. Elsamadicy
AKAndrew B. Koo
Andrew B. Koo
BRBenjamin C. Reeves
Benjamin C. Reeves
IFIsaac G. Freedman
Isaac G. Freedman
Zach PenningtonZach Pennington
Zach Pennington
Daniel M. SciubbaDaniel M. Sciubba
Daniel M. Sciubba

28 July 2021 in Global Spine Journal
Verified
Journal Article
Open access
PDF file
Aladine A. ElsamadicyAladine A. Elsamadicy
Aladine A. Elsamadicy
IFIsaac Freedman
Isaac Freedman
AKAndrew B. Koo
Andrew B. Koo
WDWyatt B. David
Wyatt B. David
BRBenjamin C. Reeves
Benjamin C. Reeves
Daniel M. SciubbaDaniel M. Sciubba
Daniel M. Sciubba
Retrospective cohort study. The influence that race has on mortality rates in patients with spinal cord tumors is relatively unknown. The aim of this study was to investigate the influence of race on the outcomes of patients with primary malignant or nonmalignant tumors of the spinal cord or spinal meninges. The Surveillance, Epidemiology, and End Results (SEER) Registry was used to identify all patients with a code for primary malignant or nonmalignant tumor of the spinal cord (C72.0) or spinal meninges (C70.1) from 1973 through 2016. Racial groups (African-American/Black vs. White) were balanced using propensity-score (PS) matching using a non-parsimonious 1:1 nearest neighbor matching algorithm. Overall survival (OS) estimates were obtained using the Kaplan-Meier method and compared across non-PS-matched and PS-matched groups using log-rank tests. Associations of survival with clinical variables was assessed using doubly robust Cox proportional-hazards (CPH) regression analysis. There were a total of 7,498 patients identified with 648 (6.8%) being African American. African-American patients with primary intradural spine tumors were more likely to die of all causes than were White patients in both the non-PS-matched [HR: 1.26, 95% CI: (1.04, 1.51), P = 0.01] and PS-matched cohorts [HR: 1.64, 95% CI: (1.28, 2.11), P < 0.0001]. On multivariate CPH regression analysis age at diagnosis [HR: 1.03, 95% CI: (1.02, 1.05), P < 0.0001], race [HR: 1.82, 95% CI: (1.22, 2.74), P = 0.004), and receipt of RT [HR: 2.62, 95% CI: (1.56, 4.37), P = 0.0002) were all significantly associated with all-cause mortality, when controlling for other demographic, tumor, and treatment variables. Our study provides population-based estimates of the prognosis for patients with primary malignant or nonmalignant tumors of the spinal cord or spinal meninges and suggests that race may impact all-cause mortality.

28 February 2025 in Acute and Critical Care
Verified
Journal Article
Open access
PDF file
CHChristopher Hong
Christopher Hong
MEMuhammad K. Effendi
Muhammad K. Effendi
AAAbdalla A. Ammar
Abdalla A. Ammar
KOKent A. Owusu
Kent A. Owusu
MAMahmoud A. Ammar
Mahmoud A. Ammar
MLMark L. Landreneau
Mark L. Landreneau
Hypotension secondary to autonomic dysfunction is a common complication of acute spinal cord injury (SCI) that may worsen neurologic outcomes. Midodrine, an enteral α-1 agonist, is often used to facilitate weaning intravenous (IV) vasopressors, but its use can be limited by reflex bradycardia. Alternative enteral agents to facilitate this wean in the acute post-SCI setting have not been described. We aim to describe novel application of droxidopa, an enteral precursor of norepinephrine that is approved to treat neurogenic orthostatic hypotension, in the acute post-SCI setting. Droxidopa may be an alternative enteral therapy for those intolerant of midodrine due to reflex bradycardia. We describe two patients suffering traumatic cervical SCI who were successfully weaned off IV vasopressors with droxidopa after failing with midodrine. The first patient was a 64-year-old male who underwent C3–6 laminectomies and fusion after a ten-foot fall resulting in quadriparesis. Post-operatively, the addition of midodrine in an attempt to wean off IV vasopressors resulted in significant reflexive bradycardia. Treatment with droxidopa facilitated rapidly weaning IV vasopressors and transfer to a lower level of care within 72 hours of treatment initiation. The second patient was a 73-year-old male who underwent C3–5 laminectomies and fusion for a traumatic hyperflexion injury causing paraplegia. The addition of midodrine resulted in severe bradycardia, prompting consideration of pacemaker placement. However, with the addition of droxidopa, this was avoided, and the patient was weaned off IV vasopressors on dual oral therapy with midodrine and droxidopa. Droxidopa may be a viable enteral therapy to treat hypotension in patients after acute SCI who are otherwise not tolerating midodrine in order to wean off IV vasopressors. This strategy may avoid pacemaker placement and facilitate shorter stays in the intensive care unit, particularly for patients who are stable but require continued intensive care unit admission for IV vasopressors, which can be cost ineffective and human resource depleting.